The planned retirement is orderly with a six-month transition period and potential board retention, reducing immediate leadership risk. Monitor for any successor appointment for the President of R&D role and for the Board's decision on Dr. Kelsey's directorship. No trading catalyst from this filing.
Price Chart
Executive Summary
Revolution Medicines filed an 8-K announcing the planned retirement of President of R&D Steve Kelsey, effective January 4, 2027, with a transition to senior advisor starting July 1, 2026, and a contemplated board appointment. The filing also reports routine annual meeting results, including the election of two Class III directors and ratification of the auditor. No financial data or material business changes were disclosed.
Key Facts
- Steve Kelsey, M.D., President of Research and Development, intends to retire effective January 4, 2027.
- Dr. Kelsey will transition to Senior Advisor to the CEO from July 1, 2026, until retirement.
- The company contemplates appointing Dr. Kelsey to the Board of Directors upon his retirement, subject to Board approval.
- Annual meeting results: Alexis Borisy and Mark A. Goldsmith elected as Class III directors; PwC ratified as auditor; advisory say-on-pay approved.
Financial Impact
No financial impact from this filing.
Risk Factors
- Potential loss of key R&D leadership if transition does not proceed as planned.
- Successor not yet named, creating uncertainty in R&D pipeline execution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-276718 |
| Document: 0001193125-26-276718-index-headers.html | 0001193125-26-276718 |
| Document: 0001193125-26-276718-index.html | 0001193125-26-276718 |
| Document: 0001193125-26-276718.txt | 0001193125-26-276718 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 17d ago | Insider Cluster | $204.86 $190.95 | ▼ −6.79% | ▼ −7.61% | $206.29 (+0.70%) |
Sep 14, 2026 17d ago | Insider Cluster | $204.86 $192.86 | ▼ −5.86% | ▼ −7.98% | $206.29 (+0.70%) |
Aug 26, 2026 5w ago | 8-K | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 26, 2026 5w ago | Press Release | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 25, 2026 5w ago | Insider Cluster | $211.38 $209.87 | ▼ −0.71% | ▼ −0.18% | $206.29 (−2.41%) |
Jul 2, 2026 13w ago | Press Release | $189.24 $191.13 | ▲ +1.00% | ▲ +0.07% | $206.29 (+9.01%) |
Jul 1, 2026 13w ago | Insider Cluster | $187.51 $190.46 | ▲ +1.57% | ▲ +1.31% | $206.29 (+10.02%) |
Jun 22, 2026 14w ago | 8-K | $165.81 $192.62 | ▲ +16.17% | ▲ +16.62% | $206.29 (+24.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access